Drug intelligence / Profile preview

Nanjing Sanhome Pharma ALK5 compound 8h

Development stage: Unknown
Lead developer: Nanjing Sanhome Pharmaceutical

Overview

Nanjing Sanhome Pharma ALK5 compound 8h: sourced facts only. name: "Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively." [PMID:35051574]; target: "Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively." [PMID:35051574]; developer: "School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China; R &D Center, Nanjing Sanhome Pharmaceutical Co. Ltd., Nanjing, Jiangsu 211135, China." [PMID:35051574]; stage: "More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity." [PMID:35051574]

Targets

TGFBR1

Beyond the preview

Go deeper on Nanjing Sanhome Pharma ALK5 compound 8h.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Sanhome Pharma ALK5 compound 8h.